Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy.
<h4>Background</h4>To compare the incidence and timing of toxicity associated with the use of a reduced dose of stavudine from 40 to 30 mg in first-line antiretroviral therapy (ART) for HIV treatment and to investigate associated risk factors.<h4>Methods</h4>Multicohort study...
Guardado en:
Autores principales: | Mar Pujades-Rodríguez, Emmanuelle Dantony, Loretxu Pinoges, René Ecochard, Jean-François Etard, Esther Carrillo-Casas, Elisabeth Szumilin, AIDS Working Group of Médecins Sans Frontières |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/55981807dc624f34a168e91a1d0f1a79 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment.
por: Thong Phe, et al.
Publicado: (2013) -
Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia.
por: Janin Nouhin, et al.
Publicado: (2013) -
A day for freedom
por: Reporters Sans Frontieres
Publicado: (1996) -
Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy.
por: Pere Domingo, et al.
Publicado: (2013) -
The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.
por: Lachlan R Gray, et al.
Publicado: (2013)